Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,377Revenue $M7.0Net Margin (%)-667.6Z-Score46.1
Enterprise Value $M1,222EPS $-0.6Operating Margin %-672.6F-Score2
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-667.6Higher ROA y-yN
Price/Book9.410-y EBITDA Growth Rate %0Quick Ratio9.6Cash flow > EarningsY
Price/Sales1275-y EBITDA Growth Rate %0Current Ratio9.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-76.9Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-102.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M91.5ROI % (ttm)-34.8Gross Margin Increase y-yN

Gurus Latest Trades with KERX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
KERXSeth Klarman 2014-03-31 Buy 2.6%$12.16 - $16.88
($14.98)
$ 15.050%New holding, 6310850 sh.6,310,850
KERXJohn Burbank 2012-12-31 Sold Out -0.06%$2.31 - $3.14
($2.72)
$ 15.05453%Sold Out0
KERXJohn Burbank 2012-09-30 Buy 0.06%$1.79 - $2.83
($2.08)
$ 15.05624%New holding, 500000 sh.500,000
KERXGeorge Soros 2006-09-30 Sold Out -0.04%$9.8 - $13.84
($12.1)
$ 15.0524%Sold Out0
KERXGeorge Soros 2006-06-30 Buy 0.04%$12.64 - $17.44
($15.3)
$ 15.05-2%New holding, 30000 sh.30,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

KERX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
KERX Seth Klarman 2014-03-316,310,8506.92.6New Buy
Premium Most recent portfolio changes are included for Premium Members only!


KERX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BENTSUR RONCEO 2014-07-07Sell1,788$15.75-2.54view
Oliviero James F IIICFO 2014-07-07Sell2,054$15.75-2.54view
BENTSUR RONCEO 2014-04-03Sell1,816$16.46-6.74view
Oliviero James F IIICFO 2014-04-03Sell2,087$16.46-6.74view
Oliviero James F IIICFO 2014-03-21Sell292,483$15.141.39view
Oliviero James F IIICFO 2014-01-03Sell6,309$12.5722.12view
BENTSUR RONCEO 2014-01-03Sell5,257$12.5722.12view
Oliviero James F IIICFO 2013-12-30Sell109,500$12.6421.44view
BENTSUR RONCEO 2013-10-03Sell2,505$10.2549.76view
Oliviero James F IIICFO 2013-10-03Sell1,475$10.2549.76view

Press Releases about KERX :

    Quarterly/Annual Reports about KERX:

    News about KERX:

    Articles On GuruFocus.com
    Seth Klarman Tops Guru Scoreboard for First Half 2014 Jul 05 2014 
    Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
    Weekly Insider Sells Highlight: KERX, ORCL, QCOM, GILD Mar 24 2014 
    Weekly Insider Sells Highlight: FLT, KERX, KOG, MEI, HTZ Jan 06 2014 
    comment on KERX Mar 02 2013 
    Can Keryx Succeed Without Partnership? Apr 24 2012 
    Keryx Still Has High Potential from Zerenex Apr 12 2012 
    Bio drug Nov 03 2011 
    comment on KERX Oct 26 2011 
    Keryx Biopharmaceuticals Inc. (KERX) CFO James F Iii Oliviero sells 14,064 Shares Jan 03 2011 


    More From Other Websites
    Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the... Jul 24 2014
    Keryx drug improves phosphorus, iron in kidney patients -trial Jul 24 2014
    Zerenex(TM) (Ferric Citrate) Long-Term Phase 3 Study Results Published in the Journal of the... Jul 24 2014
    Keryx Biopharmaceuticals, Inc. to Present at the 9th Annual JMP Securities Healthcare Conference Jul 17 2014
    Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally... Jul 17 2014
    KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 24 2014
    Keryx Biopharmaceuticals: Baupost Group's New Position Suggests A Possible Takeout And 100%+ Gains Jun 24 2014
    Keryx Biopharmaceuticals Announces Issuance of Two U.S. Patents for Zerenex(TM) Covering Orally... Jun 18 2014
    Keryx Biopharmaceuticals, Inc. to Present at the 9th Annual JMP Securities Healthcare Conference Jun 17 2014
    The Baupost Group buys a new position in Keryx Biopharmaceuticals Jun 06 2014
    Must-know highlights of the Baupost Group’s 1Q 2014 positions Jun 05 2014
    Keryx Biopharmaceuticals, Inc. to Present at the 35th Annual Goldman Sachs Global Healthcare... Jun 05 2014
    Keryx Biopharma: Approval Delay Does Not Change Zerenex Prospects Or Differentiation May 29 2014
    Options with decreasing implied volatility May 23 2014
    Keryx PDUFA extension creates buying opportunity, says Oppenheimer May 23 2014
    KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 22 2014
    Keryx announces FDA extends PDUFA date for Zerenex May 22 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide